The improvement of rimaprost in residual symptoms in patients after spinal decompression for spinal cervical spondylosis: a prospective randomised controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500098336

Enrollment

Unknown

Registered

2025-03-06

Start date

2023-11-11

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Residual symptoms after cervical decompression of the spinal canal

Interventions

Experimental group:Rimaprost 5ug tid applied continuously for 1 month

control group:Continuous NSAIDs (etoricoxib 100mg, BID) and methylcobalamin (methylcobalamin, 500ug qd) at 1 month postoperatively

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. patients with cervical spinal spinal stenosis; 2. residual symptoms (pain and/or numbness); 3. >18 years (male or female);

Exclusion criteria

Exclusion criteria: 1. patients with a history of spinal surgery; 2. patients combined with scoliosis; 3. patients with severe liver, renal, or cardiovascular disease; 4. People who refuse to participate.

Design outcomes

Primary

Measure	Time frame
NDI;	—

Secondary

Measure	Time frame
VAS of pain;VAS of numb;Incidence of adverse events during follow-up;Dose of analgesic drugs taken 1 month after surgery;Postoperative hospital stay;Side effects of NSAID;Patient satisfaction;Patient satisfaction;	—

Countries

China

Contacts

Public ContactXinyu Liu

Qilu Hospital of Shandong University

newyuliu@163.com+86 185 6008 2585

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026